Champions Oncology, Inc. (CSBR) 10-Year Financial Performance & Capital Metrics

CSBR • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

AboutChampions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.Show more

Revenue $57M +13.5%
EBITDA $6M +228.3%
Net Income $5M +164.6%
EPS (Diluted) 0.33 +161.1%
Gross Margin 47.27% +14.2%
EBITDA Margin 11.39% +213.0%
Operating Margin 8.51% +161.7%
Net Margin 8.26% +156.9%
ROE 503.05% +194.5%
ROIC 242.22% +240.6%
Debt/Equity 1.62
Interest Coverage 179.48 +172.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 12.1%
✓Efficient asset utilization: 1.8x turnover

✗Weaknesses

✗Trading more than 30% below 52-week high
✗Expensive at 27.1x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y20.44%

5Y12.13%

3Y5.06%

TTM9.06%

Profit (Net Income) CAGR

10Y-

5Y-

3Y104.71%

TTM522.07%

EPS CAGR

10Y-

5Y-

3Y104.3%

TTM417.3%

ROCE

10Y Avg-182.81%

5Y Avg-5.85%

3Y Avg-11.91%

Latest74.09%

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Sales/Revenue+	11.18M	15.41M	20.24M	27.07M	32.12M	41.04M	49.11M	53.87M	50.16M	56.94M
Revenue Growth %	0.26%	0.38%	0.31%	0.34%	0.19%	0.28%	0.2%	0.1%	-0.07%	0.14%
Cost of Goods Sold+	8.69M	9.7M	10.55M	14.27M	17M	21.45M	23.63M	29.53M	29.4M	30.03M
COGS % of Revenue	0.78%	0.63%	0.52%	0.53%	0.53%	0.52%	0.48%	0.55%	0.59%	0.53%
Gross Profit+	2.5M	5.71M	9.69M	12.8M	15.12M	19.59M	25.48M	24.34M	20.75M	26.91M
Gross Margin %	0.22%	0.37%	0.48%	0.47%	0.47%	0.48%	0.52%	0.45%	0.41%	0.47%
Gross Profit Growth %	1.03%	1.29%	0.7%	0.32%	0.18%	0.3%	0.3%	-0.04%	-0.15%	0.3%
Operating Expenses+	12.81M	12.52M	11.04M	12.53M	16.71M	19.23M	24.87M	28.79M	27.68M	22.07M
OpEx % of Revenue	1.15%	0.81%	0.55%	0.46%	0.52%	0.47%	0.51%	0.53%	0.55%	0.39%
Selling, General & Admin	8.62M	8.22M	6.64M	7.73M	10.86M	12.03M	15.5M	17.24M	18.13M	15.24M
SG&A % of Revenue	0.77%	0.53%	0.33%	0.29%	0.34%	0.29%	0.32%	0.32%	0.36%	0.27%
Research & Development	4.19M	4.29M	4.4M	4.8M	5.85M	7.2M	9.37M	11.54M	9.54M	6.83M
R&D % of Revenue	0.38%	0.28%	0.22%	0.18%	0.18%	0.18%	0.19%	0.21%	0.19%	0.12%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-10.32M	-6.81M	-1.35M	270K	-1.59M	366K	607K	-4.45M	-6.92M	4.85M
Operating Margin %	-0.92%	-0.44%	-0.07%	0.01%	-0.05%	0.01%	0.01%	-0.08%	-0.14%	0.09%
Operating Income Growth %	0.22%	0.34%	0.8%	1.2%	-6.87%	1.23%	0.66%	-8.33%	-0.56%	1.7%
EBITDA+	-10.16M	-6.64M	-994K	876K	-358K	1.95M	3.02M	-1.25M	-5.05M	6.49M
EBITDA Margin %	-0.91%	-0.43%	-0.05%	0.03%	-0.01%	0.05%	0.06%	-0.02%	-0.1%	0.11%
EBITDA Growth %	0.22%	0.35%	0.85%	1.88%	-1.41%	6.44%	0.55%	-1.41%	-3.04%	2.28%
D&A (Non-Cash Add-back)	156K	168K	360K	606K	1.23M	1.58M	2.41M	3.2M	1.87M	1.64M
EBIT	-10.35M	-6.87M	-1.44M	231K	-1.96M	437K	583K	-5.27M	-7.28M	4.65M
Net Interest Income+	0	0	0	0	0	0	-24K	0	64K	60K
Interest Income	0	0	0	0	0	0	0	0	92K	87K
Interest Expense	0	0	0	0	0	0	24K	0	28K	27K
Other Income/Expense	-38K	-56K	-89K	-39K	-377K	71K	-24K	-818K	-387K	-220K
Pretax Income+	-10.35M	-6.87M	-1.44M	231K	-1.96M	437K	583K	-5.27M	-7.31M	4.63M
Pretax Margin %	-0.93%	-0.45%	-0.07%	0.01%	-0.06%	0.01%	0.01%	-0.1%	-0.15%	0.08%
Income Tax+	92K	19K	33K	103K	130K	75K	35K	68K	-32K	-75K
Effective Tax Rate %	1.01%	1%	1.02%	0.55%	1.07%	0.83%	0.94%	1.01%	1%	1.02%
Net Income+	-10.45M	-6.88M	-1.48M	128K	-2.09M	362K	548K	-5.33M	-7.28M	4.7M
Net Margin %	-0.93%	-0.45%	-0.07%	0%	-0.07%	0.01%	0.01%	-0.1%	-0.15%	0.08%
Net Income Growth %	0.21%	0.34%	0.79%	1.09%	-17.35%	1.17%	0.51%	-10.74%	-0.36%	1.65%
Net Income (Continuing)	-10.45M	-6.88M	-1.48M	128K	-2.09M	362K	548K	-5.33M	-7.28M	4.7M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.20	-0.63	-0.13	0.01	-0.18	0.02	0.04	-0.39	-0.54	0.33
EPS Growth %	0.21%	0.47%	0.79%	1.07%	-	1.14%	0.56%	-11.08%	-0.38%	1.61%
EPS (Basic)	-1.20	-0.64	-0.13	0.01	-0.18	0.03	0.04	-0.39	-0.54	0.34
Diluted Shares Outstanding	8.7M	10.98M	11M	14.1M	11.84M	14.57M	14.16M	13.54M	13.55M	14.27M
Basic Shares Outstanding	8.7M	10.68M	10.99M	11.34M	11.84M	13.14M	13.2M	13.54M	13.55M	13.66M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Total Current Assets+	4.34M	5.87M	5.06M	7.92M	13.5M	12.63M	19.66M	19.46M	13.64M	22.37M
Cash & Short-Term Investments	2.58M	3.29M	856K	3.24M	8.34M	4.69M	9.01M	10.12M	2.62M	9.79M
Cash Only	2.58M	3.29M	856K	3.24M	8.34M	4.69M	9.01M	10.12M	2.62M	9.79M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.31M	2.27M	3.92M	4.38M	4.77M	6.99M	9.51M	8.01M	9.53M	11.23M
Days Sales Outstanding	42.83	53.86	70.63	59.02	54.2	62.13	70.7	54.28	69.32	72.01
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	1.33M	1.5M	1.35M
Total Non-Current Assets+	1.44M	2.14M	3.02M	3.34M	7.25M	14.96M	15.71M	14.85M	12.49M	9.97M
Property, Plant & Equipment	618K	1.22M	2.08M	2.55M	6.79M	14.61M	15.36M	14.5M	11.97M	9.46M
Fixed Asset Turnover	18.09x	12.67x	9.72x	10.63x	4.73x	2.81x	3.20x	3.71x	4.19x	6.02x
Goodwill	669K	669K	669K	669K	335K	335K	335K	335K	335K	335K
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	-19.07M	-21.82M	150K	0	0	0	0	0	0	0
Other Non-Current Assets	150K	257K	266K	128K	128K	15K	15K	15K	185K	185K
Total Assets+	5.78M	8.01M	8.08M	11.27M	20.75M	27.59M	35.38M	34.31M	26.13M	32.34M
Asset Turnover	1.94x	1.92x	2.51x	2.40x	1.55x	1.49x	1.39x	1.57x	1.92x	1.76x
Asset Growth %	-0.52%	0.39%	0.01%	0.39%	0.84%	0.33%	0.28%	-0.03%	-0.24%	0.24%
Total Current Liabilities+	5.31M	7.45M	7.48M	8.03M	12.3M	11.2M	17.48M	21.73M	21.54M	23.85M
Accounts Payable	1.9M	1.85M	2.15M	2.81M	3.14M	1.89M	2.87M	5.33M	5.8M	4.25M
Days Payables Outstanding	79.67	69.67	74.5	71.82	67.42	32.23	44.3	65.93	72	51.63
Short-Term Debt	24K	25K	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	-24K	-25K	29K	0	0	0	72K	145K	150K	135K
Current Ratio	0.82x	0.79x	0.68x	0.99x	1.10x	1.13x	1.13x	0.90x	0.63x	0.94x
Quick Ratio	0.82x	0.79x	0.68x	0.99x	1.10x	1.13x	1.13x	0.90x	0.63x	0.94x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	233K	164K	621K	1M	3.35M	8.96M	8.8M	7.94M	6.49M	4.72M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	17K	0	3.17M	8.78M	8.41M	7.39M	6.09M	4.63M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	233K	164K	604K	1M	178K	181K	391K	551K	401K	85K
Total Liabilities	5.54M	7.61M	8.1M	9.03M	15.65M	20.16M	26.28M	29.68M	28.04M	28.57M
Total Debt+	83K	63K	43K	16K	3.8M	9.6M	9.47M	8.6M	7.43M	6.11M
Net Debt	-2.5M	-3.23M	-814K	-3.22M	-4.54M	4.91M	459K	-1.52M	4.81M	-3.68M
Debt / Equity	0.35x	0.16x	-	0.01x	0.74x	1.29x	1.04x	1.85x	-	1.62x
Debt / EBITDA	-	-	-	0.02x	-	4.93x	3.13x	-	-	0.94x
Net Debt / EBITDA	-	-	-	-3.68x	-	2.52x	0.15x	-	-	-0.57x
Interest Coverage	-	-	-	-	-	-	25.29x	-	-247.18x	179.48x
Total Equity+	238K	400K	-25K	2.24M	5.1M	7.43M	9.1M	4.64M	-1.9M	3.77M
Equity Growth %	-0.97%	0.68%	-1.06%	90.52%	1.28%	0.46%	0.22%	-0.49%	-1.41%	2.98%
Book Value per Share	0.03	0.04	-0.00	0.16	0.43	0.51	0.64	0.34	-0.14	0.26
Total Shareholders' Equity	238K	400K	3K	2.24M	5.1M	7.43M	9.1M	4.64M	-1.9M	3.77M
Common Stock	9K	11K	11K	12K	13K	13K	14K	14K	14K	14K
Retained Earnings	-62.47M	-69.35M	-70.83M	-70.7M	-72.89M	-72.53M	-71.98M	-77.32M	-84.59M	-79.89M
Treasury Stock	-1.25M	-1.25M	-1.25M	0	0	0	0	-74K	-708K	-708K
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Cash from Operations+	-6.45M	-2.84M	-1.23M	1.86M	2.9M	-1.68M	6.5M	3.96M	-6.14M	7.39M
Operating CF Margin %	-0.58%	-0.18%	-0.06%	0.07%	0.09%	-0.04%	0.13%	0.07%	-0.12%	0.13%
Operating CF Growth %	0.33%	0.56%	0.57%	2.52%	0.56%	-1.58%	4.86%	-0.39%	-2.55%	2.2%
Net Income	-10.45M	-6.88M	-1.5M	128K	-1.98M	334K	548K	-5.33M	-7.28M	4.7M
Depreciation & Amortization	156K	168K	360K	606K	825K	1.18M	1.63M	2.25M	1.87M	1.64M
Stock-Based Compensation	2.6M	2.66M	1M	636K	600K	598K	912K	864K	1.12M	654K
Deferred Taxes	65K	24K	-44K	71K	560K	49K	0	1M	0	0
Other Non-Cash Items	30K	44K	491K	410K	403K	323K	1.07M	952K	1.98M	1.01M
Working Capital Changes	1.14M	1.15M	-1.53M	11K	2.49M	-4.17M	2.34M	4.23M	-3.82M	-621K
Change in Receivables	-282K	-986K	-1.6M	-531K	-670K	-2.27M	-2.82M	1.31M	-1.99M	-1.44M
Change in Inventory	-199K	404K	-27K	571K	1.04M	-1.1M	0	0	0	0
Change in Payables	482K	-43K	301K	653K	333K	-1.25M	974K	2.46M	465K	-1.75M
Cash from Investing+	-322K	-766K	-1.23M	-834K	-2.22M	-3.17M	-2.38M	-2.87M	-836K	-389K
Capital Expenditures	-322K	-766K	-1.23M	-834K	-2.22M	-3.28M	-2.38M	-2.87M	-836K	-389K
CapEx % of Revenue	0.03%	0.05%	0.06%	0.03%	0.07%	0.08%	0.05%	0.05%	0.02%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	112K	0	0	0	0
Cash from Financing+	2K	4.32M	13K	1.2M	4.42M	1.2M	207K	11K	-527K	170K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-18K	0	0	0	0	0	0	85K	253K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-6.77M	-3.61M	-2.46M	1.03M	685K	-4.96M	4.11M	1.08M	-6.97M	7M
FCF Margin %	-0.61%	-0.23%	-0.12%	0.04%	0.02%	-0.12%	0.08%	0.02%	-0.14%	0.12%
FCF Growth %	0.31%	0.47%	0.32%	1.42%	-0.33%	-8.24%	1.83%	-0.74%	-7.44%	2%
FCF per Share	-0.78	-0.33	-0.22	0.07	0.06	-0.34	0.29	0.08	-0.51	0.49
FCF Conversion (FCF/Net Income)	0.62x	0.41x	0.83x	14.55x	-1.39x	-4.64x	11.86x	-0.74x	0.84x	1.57x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-251.8%	-2157.99%	-787.2%	11.57%	-57.05%	5.78%	6.63%	-77.7%	-532.46%	503.05%
Return on Invested Capital (ROIC)	-	-	-	-	-214.32%	4.26%	4.16%	-52.66%	-172.28%	242.22%
Gross Margin	22.32%	37.04%	47.86%	47.3%	47.08%	47.74%	51.88%	45.18%	41.38%	47.27%
Net Margin	-93.42%	-44.67%	-7.29%	0.47%	-6.52%	0.88%	1.12%	-9.9%	-14.51%	8.26%
Debt / Equity	0.35x	0.16x	-	0.01x	0.74x	1.29x	1.04x	1.85x	-	1.62x
Interest Coverage	-	-	-	-	-	-	25.29x	-	-247.18x	179.48x
FCF Conversion	0.62x	0.41x	0.83x	14.55x	-1.39x	-4.64x	11.86x	-0.74x	0.84x	1.57x
Revenue Growth	26.16%	37.82%	31.34%	33.72%	18.68%	27.76%	19.66%	9.69%	-6.9%	13.54%

Revenue by Segment

	2015	2016	2017	2019	2020	2021	2022	2023	2024	2025
Pharmacology Services	-	-	-	25.48M	31.26M	39.47M	46.83M	50.71M	47.03M	48.59M
Pharmacology Services Growth	-	-	-	-	22.67%	26.27%	18.65%	8.27%	-7.24%	3.30%
License and Maintenance	-	-	-	-	-	-	-	-	-	4.68M
License and Maintenance Growth	-	-	-	-	-	-	-	-	-	-
Product and Service, Other	-	-	-	-	-	-	-	-	3.1M	3.68M
Product and Service, Other Growth	-	-	-	-	-	-	-	-	-	18.73%
Personalized Oncology Services	-	-	-	1.28M	790K	166K	49K	116K	18K	-
Personalized Oncology Services Growth	-	-	-	-	-38.14%	-78.99%	-70.48%	136.73%	-84.48%	-
Other Services	-	-	-	306K	71K	1.4M	2.23M	3.05M	-	-
Other Services Growth	-	-	-	-	-76.80%	1873.24%	58.96%	36.78%	-	-
Consolidated	8.86M	11.18M	15.41M	-	-	-	-	-	-	-
Consolidated Growth	-	26.16%	37.82%	-	-	-	-	-	-	-
Translational Oncology Solutions	7.2M	9.21M	13.69M	-	-	-	-	-	-	-
Translational Oncology Solutions Growth	-	27.92%	48.65%	-	-	-	-	-	-	-
Personalized Oncology Solutions	1.66M	1.97M	1.72M	-	-	-	-	-	-	-
Personalized Oncology Solutions Growth	-	18.58%	-12.78%	-	-	-	-	-	-	-
Unallocated Corporate Overhead	-	-	-	-	-	-	-	-	-	-
Unallocated Corporate Overhead Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Champions Oncology, Inc. (CSBR) has a price-to-earnings (P/E) ratio of 21.7x. This is roughly in line with market averages.

Growth & Financials

Champions Oncology, Inc. (CSBR) reported $58.4M in revenue for fiscal year 2025. This represents a 717% increase from $7.1M in 2012.

Champions Oncology, Inc. (CSBR) grew revenue by 13.5% over the past year. This is steady growth.

Yes, Champions Oncology, Inc. (CSBR) is profitable, generating $2.5M in net income for fiscal year 2025 (8.3% net margin).

Dividend & Returns

Champions Oncology, Inc. (CSBR) has a return on equity (ROE) of 503.0%. This is excellent, indicating efficient use of shareholder capital.

Champions Oncology, Inc. (CSBR) generated $5.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Champions Oncology, Inc. (CSBR) 10-Year Financial Performance & Capital Metrics

CSBR • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

Revenue $57M +13.5%
EBITDA $6M +228.3%
Net Income $5M +164.6%
EPS (Diluted) 0.33 +161.1%
Gross Margin 47.27% +14.2%
EBITDA Margin 11.39% +213.0%
Operating Margin 8.51% +161.7%
Net Margin 8.26% +156.9%
ROE 503.05% +194.5%
ROIC 242.22% +240.6%
Debt/Equity 1.62
Interest Coverage 179.48 +172.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 12.1%
✓Efficient asset utilization: 1.8x turnover

✗Weaknesses

✗Trading more than 30% below 52-week high
✗Expensive at 27.1x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y20.44%

5Y12.13%

3Y5.06%

TTM9.06%

Profit (Net Income) CAGR

10Y-

5Y-

3Y104.71%

TTM522.07%

EPS CAGR

10Y-

5Y-

3Y104.3%

TTM417.3%

ROCE

10Y Avg-182.81%

5Y Avg-5.85%

3Y Avg-11.91%

Latest74.09%

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Sales/Revenue+	11.18M	15.41M	20.24M	27.07M	32.12M	41.04M	49.11M	53.87M	50.16M	56.94M
Revenue Growth %	0.26%	0.38%	0.31%	0.34%	0.19%	0.28%	0.2%	0.1%	-0.07%	0.14%
Cost of Goods Sold+	8.69M	9.7M	10.55M	14.27M	17M	21.45M	23.63M	29.53M	29.4M	30.03M
COGS % of Revenue	0.78%	0.63%	0.52%	0.53%	0.53%	0.52%	0.48%	0.55%	0.59%	0.53%
Gross Profit+	2.5M	5.71M	9.69M	12.8M	15.12M	19.59M	25.48M	24.34M	20.75M	26.91M
Gross Margin %	0.22%	0.37%	0.48%	0.47%	0.47%	0.48%	0.52%	0.45%	0.41%	0.47%
Gross Profit Growth %	1.03%	1.29%	0.7%	0.32%	0.18%	0.3%	0.3%	-0.04%	-0.15%	0.3%
Operating Expenses+	12.81M	12.52M	11.04M	12.53M	16.71M	19.23M	24.87M	28.79M	27.68M	22.07M
OpEx % of Revenue	1.15%	0.81%	0.55%	0.46%	0.52%	0.47%	0.51%	0.53%	0.55%	0.39%
Selling, General & Admin	8.62M	8.22M	6.64M	7.73M	10.86M	12.03M	15.5M	17.24M	18.13M	15.24M
SG&A % of Revenue	0.77%	0.53%	0.33%	0.29%	0.34%	0.29%	0.32%	0.32%	0.36%	0.27%
Research & Development	4.19M	4.29M	4.4M	4.8M	5.85M	7.2M	9.37M	11.54M	9.54M	6.83M
R&D % of Revenue	0.38%	0.28%	0.22%	0.18%	0.18%	0.18%	0.19%	0.21%	0.19%	0.12%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-10.32M	-6.81M	-1.35M	270K	-1.59M	366K	607K	-4.45M	-6.92M	4.85M
Operating Margin %	-0.92%	-0.44%	-0.07%	0.01%	-0.05%	0.01%	0.01%	-0.08%	-0.14%	0.09%
Operating Income Growth %	0.22%	0.34%	0.8%	1.2%	-6.87%	1.23%	0.66%	-8.33%	-0.56%	1.7%
EBITDA+	-10.16M	-6.64M	-994K	876K	-358K	1.95M	3.02M	-1.25M	-5.05M	6.49M
EBITDA Margin %	-0.91%	-0.43%	-0.05%	0.03%	-0.01%	0.05%	0.06%	-0.02%	-0.1%	0.11%
EBITDA Growth %	0.22%	0.35%	0.85%	1.88%	-1.41%	6.44%	0.55%	-1.41%	-3.04%	2.28%
D&A (Non-Cash Add-back)	156K	168K	360K	606K	1.23M	1.58M	2.41M	3.2M	1.87M	1.64M
EBIT	-10.35M	-6.87M	-1.44M	231K	-1.96M	437K	583K	-5.27M	-7.28M	4.65M
Net Interest Income+	0	0	0	0	0	0	-24K	0	64K	60K
Interest Income	0	0	0	0	0	0	0	0	92K	87K
Interest Expense	0	0	0	0	0	0	24K	0	28K	27K
Other Income/Expense	-38K	-56K	-89K	-39K	-377K	71K	-24K	-818K	-387K	-220K
Pretax Income+	-10.35M	-6.87M	-1.44M	231K	-1.96M	437K	583K	-5.27M	-7.31M	4.63M
Pretax Margin %	-0.93%	-0.45%	-0.07%	0.01%	-0.06%	0.01%	0.01%	-0.1%	-0.15%	0.08%
Income Tax+	92K	19K	33K	103K	130K	75K	35K	68K	-32K	-75K
Effective Tax Rate %	1.01%	1%	1.02%	0.55%	1.07%	0.83%	0.94%	1.01%	1%	1.02%
Net Income+	-10.45M	-6.88M	-1.48M	128K	-2.09M	362K	548K	-5.33M	-7.28M	4.7M
Net Margin %	-0.93%	-0.45%	-0.07%	0%	-0.07%	0.01%	0.01%	-0.1%	-0.15%	0.08%
Net Income Growth %	0.21%	0.34%	0.79%	1.09%	-17.35%	1.17%	0.51%	-10.74%	-0.36%	1.65%
Net Income (Continuing)	-10.45M	-6.88M	-1.48M	128K	-2.09M	362K	548K	-5.33M	-7.28M	4.7M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.20	-0.63	-0.13	0.01	-0.18	0.02	0.04	-0.39	-0.54	0.33
EPS Growth %	0.21%	0.47%	0.79%	1.07%	-	1.14%	0.56%	-11.08%	-0.38%	1.61%
EPS (Basic)	-1.20	-0.64	-0.13	0.01	-0.18	0.03	0.04	-0.39	-0.54	0.34
Diluted Shares Outstanding	8.7M	10.98M	11M	14.1M	11.84M	14.57M	14.16M	13.54M	13.55M	14.27M
Basic Shares Outstanding	8.7M	10.68M	10.99M	11.34M	11.84M	13.14M	13.2M	13.54M	13.55M	13.66M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Total Current Assets+	4.34M	5.87M	5.06M	7.92M	13.5M	12.63M	19.66M	19.46M	13.64M	22.37M
Cash & Short-Term Investments	2.58M	3.29M	856K	3.24M	8.34M	4.69M	9.01M	10.12M	2.62M	9.79M
Cash Only	2.58M	3.29M	856K	3.24M	8.34M	4.69M	9.01M	10.12M	2.62M	9.79M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.31M	2.27M	3.92M	4.38M	4.77M	6.99M	9.51M	8.01M	9.53M	11.23M
Days Sales Outstanding	42.83	53.86	70.63	59.02	54.2	62.13	70.7	54.28	69.32	72.01
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	1.33M	1.5M	1.35M
Total Non-Current Assets+	1.44M	2.14M	3.02M	3.34M	7.25M	14.96M	15.71M	14.85M	12.49M	9.97M
Property, Plant & Equipment	618K	1.22M	2.08M	2.55M	6.79M	14.61M	15.36M	14.5M	11.97M	9.46M
Fixed Asset Turnover	18.09x	12.67x	9.72x	10.63x	4.73x	2.81x	3.20x	3.71x	4.19x	6.02x
Goodwill	669K	669K	669K	669K	335K	335K	335K	335K	335K	335K
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	-19.07M	-21.82M	150K	0	0	0	0	0	0	0
Other Non-Current Assets	150K	257K	266K	128K	128K	15K	15K	15K	185K	185K
Total Assets+	5.78M	8.01M	8.08M	11.27M	20.75M	27.59M	35.38M	34.31M	26.13M	32.34M
Asset Turnover	1.94x	1.92x	2.51x	2.40x	1.55x	1.49x	1.39x	1.57x	1.92x	1.76x
Asset Growth %	-0.52%	0.39%	0.01%	0.39%	0.84%	0.33%	0.28%	-0.03%	-0.24%	0.24%
Total Current Liabilities+	5.31M	7.45M	7.48M	8.03M	12.3M	11.2M	17.48M	21.73M	21.54M	23.85M
Accounts Payable	1.9M	1.85M	2.15M	2.81M	3.14M	1.89M	2.87M	5.33M	5.8M	4.25M
Days Payables Outstanding	79.67	69.67	74.5	71.82	67.42	32.23	44.3	65.93	72	51.63
Short-Term Debt	24K	25K	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	-24K	-25K	29K	0	0	0	72K	145K	150K	135K
Current Ratio	0.82x	0.79x	0.68x	0.99x	1.10x	1.13x	1.13x	0.90x	0.63x	0.94x
Quick Ratio	0.82x	0.79x	0.68x	0.99x	1.10x	1.13x	1.13x	0.90x	0.63x	0.94x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	233K	164K	621K	1M	3.35M	8.96M	8.8M	7.94M	6.49M	4.72M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	17K	0	3.17M	8.78M	8.41M	7.39M	6.09M	4.63M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	233K	164K	604K	1M	178K	181K	391K	551K	401K	85K
Total Liabilities	5.54M	7.61M	8.1M	9.03M	15.65M	20.16M	26.28M	29.68M	28.04M	28.57M
Total Debt+	83K	63K	43K	16K	3.8M	9.6M	9.47M	8.6M	7.43M	6.11M
Net Debt	-2.5M	-3.23M	-814K	-3.22M	-4.54M	4.91M	459K	-1.52M	4.81M	-3.68M
Debt / Equity	0.35x	0.16x	-	0.01x	0.74x	1.29x	1.04x	1.85x	-	1.62x
Debt / EBITDA	-	-	-	0.02x	-	4.93x	3.13x	-	-	0.94x
Net Debt / EBITDA	-	-	-	-3.68x	-	2.52x	0.15x	-	-	-0.57x
Interest Coverage	-	-	-	-	-	-	25.29x	-	-247.18x	179.48x
Total Equity+	238K	400K	-25K	2.24M	5.1M	7.43M	9.1M	4.64M	-1.9M	3.77M
Equity Growth %	-0.97%	0.68%	-1.06%	90.52%	1.28%	0.46%	0.22%	-0.49%	-1.41%	2.98%
Book Value per Share	0.03	0.04	-0.00	0.16	0.43	0.51	0.64	0.34	-0.14	0.26
Total Shareholders' Equity	238K	400K	3K	2.24M	5.1M	7.43M	9.1M	4.64M	-1.9M	3.77M
Common Stock	9K	11K	11K	12K	13K	13K	14K	14K	14K	14K
Retained Earnings	-62.47M	-69.35M	-70.83M	-70.7M	-72.89M	-72.53M	-71.98M	-77.32M	-84.59M	-79.89M
Treasury Stock	-1.25M	-1.25M	-1.25M	0	0	0	0	-74K	-708K	-708K
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Cash from Operations+	-6.45M	-2.84M	-1.23M	1.86M	2.9M	-1.68M	6.5M	3.96M	-6.14M	7.39M
Operating CF Margin %	-0.58%	-0.18%	-0.06%	0.07%	0.09%	-0.04%	0.13%	0.07%	-0.12%	0.13%
Operating CF Growth %	0.33%	0.56%	0.57%	2.52%	0.56%	-1.58%	4.86%	-0.39%	-2.55%	2.2%
Net Income	-10.45M	-6.88M	-1.5M	128K	-1.98M	334K	548K	-5.33M	-7.28M	4.7M
Depreciation & Amortization	156K	168K	360K	606K	825K	1.18M	1.63M	2.25M	1.87M	1.64M
Stock-Based Compensation	2.6M	2.66M	1M	636K	600K	598K	912K	864K	1.12M	654K
Deferred Taxes	65K	24K	-44K	71K	560K	49K	0	1M	0	0
Other Non-Cash Items	30K	44K	491K	410K	403K	323K	1.07M	952K	1.98M	1.01M
Working Capital Changes	1.14M	1.15M	-1.53M	11K	2.49M	-4.17M	2.34M	4.23M	-3.82M	-621K
Change in Receivables	-282K	-986K	-1.6M	-531K	-670K	-2.27M	-2.82M	1.31M	-1.99M	-1.44M
Change in Inventory	-199K	404K	-27K	571K	1.04M	-1.1M	0	0	0	0
Change in Payables	482K	-43K	301K	653K	333K	-1.25M	974K	2.46M	465K	-1.75M
Cash from Investing+	-322K	-766K	-1.23M	-834K	-2.22M	-3.17M	-2.38M	-2.87M	-836K	-389K
Capital Expenditures	-322K	-766K	-1.23M	-834K	-2.22M	-3.28M	-2.38M	-2.87M	-836K	-389K
CapEx % of Revenue	0.03%	0.05%	0.06%	0.03%	0.07%	0.08%	0.05%	0.05%	0.02%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	112K	0	0	0	0
Cash from Financing+	2K	4.32M	13K	1.2M	4.42M	1.2M	207K	11K	-527K	170K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-18K	0	0	0	0	0	0	85K	253K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-6.77M	-3.61M	-2.46M	1.03M	685K	-4.96M	4.11M	1.08M	-6.97M	7M
FCF Margin %	-0.61%	-0.23%	-0.12%	0.04%	0.02%	-0.12%	0.08%	0.02%	-0.14%	0.12%
FCF Growth %	0.31%	0.47%	0.32%	1.42%	-0.33%	-8.24%	1.83%	-0.74%	-7.44%	2%
FCF per Share	-0.78	-0.33	-0.22	0.07	0.06	-0.34	0.29	0.08	-0.51	0.49
FCF Conversion (FCF/Net Income)	0.62x	0.41x	0.83x	14.55x	-1.39x	-4.64x	11.86x	-0.74x	0.84x	1.57x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-251.8%	-2157.99%	-787.2%	11.57%	-57.05%	5.78%	6.63%	-77.7%	-532.46%	503.05%
Return on Invested Capital (ROIC)	-	-	-	-	-214.32%	4.26%	4.16%	-52.66%	-172.28%	242.22%
Gross Margin	22.32%	37.04%	47.86%	47.3%	47.08%	47.74%	51.88%	45.18%	41.38%	47.27%
Net Margin	-93.42%	-44.67%	-7.29%	0.47%	-6.52%	0.88%	1.12%	-9.9%	-14.51%	8.26%
Debt / Equity	0.35x	0.16x	-	0.01x	0.74x	1.29x	1.04x	1.85x	-	1.62x
Interest Coverage	-	-	-	-	-	-	25.29x	-	-247.18x	179.48x
FCF Conversion	0.62x	0.41x	0.83x	14.55x	-1.39x	-4.64x	11.86x	-0.74x	0.84x	1.57x
Revenue Growth	26.16%	37.82%	31.34%	33.72%	18.68%	27.76%	19.66%	9.69%	-6.9%	13.54%

Revenue by Segment

	2015	2016	2017	2019	2020	2021	2022	2023	2024	2025
Pharmacology Services	-	-	-	25.48M	31.26M	39.47M	46.83M	50.71M	47.03M	48.59M
Pharmacology Services Growth	-	-	-	-	22.67%	26.27%	18.65%	8.27%	-7.24%	3.30%
License and Maintenance	-	-	-	-	-	-	-	-	-	4.68M
License and Maintenance Growth	-	-	-	-	-	-	-	-	-	-
Product and Service, Other	-	-	-	-	-	-	-	-	3.1M	3.68M
Product and Service, Other Growth	-	-	-	-	-	-	-	-	-	18.73%
Personalized Oncology Services	-	-	-	1.28M	790K	166K	49K	116K	18K	-
Personalized Oncology Services Growth	-	-	-	-	-38.14%	-78.99%	-70.48%	136.73%	-84.48%	-
Other Services	-	-	-	306K	71K	1.4M	2.23M	3.05M	-	-
Other Services Growth	-	-	-	-	-76.80%	1873.24%	58.96%	36.78%	-	-
Consolidated	8.86M	11.18M	15.41M	-	-	-	-	-	-	-
Consolidated Growth	-	26.16%	37.82%	-	-	-	-	-	-	-
Translational Oncology Solutions	7.2M	9.21M	13.69M	-	-	-	-	-	-	-
Translational Oncology Solutions Growth	-	27.92%	48.65%	-	-	-	-	-	-	-
Personalized Oncology Solutions	1.66M	1.97M	1.72M	-	-	-	-	-	-	-
Personalized Oncology Solutions Growth	-	18.58%	-12.78%	-	-	-	-	-	-	-
Unallocated Corporate Overhead	-	-	-	-	-	-	-	-	-	-
Unallocated Corporate Overhead Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Champions Oncology, Inc. (CSBR) has a price-to-earnings (P/E) ratio of 21.7x. This is roughly in line with market averages.

Growth & Financials

Champions Oncology, Inc. (CSBR) reported $58.4M in revenue for fiscal year 2025. This represents a 717% increase from $7.1M in 2012.

Champions Oncology, Inc. (CSBR) grew revenue by 13.5% over the past year. This is steady growth.

Yes, Champions Oncology, Inc. (CSBR) is profitable, generating $2.5M in net income for fiscal year 2025 (8.3% net margin).

Dividend & Returns

Champions Oncology, Inc. (CSBR) has a return on equity (ROE) of 503.0%. This is excellent, indicating efficient use of shareholder capital.

Champions Oncology, Inc. (CSBR) generated $5.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.